Skip to content

April 30, 2026

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
Regulatory
Ray Therapeutics receives EMA PRIME status for gene therapy

Regulatory

Ray Therapeutics receives EMA PRIME status for gene therapy

Pharmaceutical Technology

Ray Therapeutics has received PRIME designation from the EMA for its RTx-015 gene therapy to treat retinitis pigmentosa (RP).

Gene Therapy Platform

Read full story

pharminent April 30, 2026 (Last updated: April 30, 2026)

Pharmaceutical Technology

Ray Therapeutics has received PRIME designation from the EMA for its RTx-015 gene therapy to treat retinitis pigmentosa (RP).

Gene Therapy Platform

Read full story

Post navigation

Previous: Survodutide delivers 16.6% weight loss in major phase 3 obesity trial

Next: Regeneron Q1 2026 net income falls 10% to $727m

Related Stories

Regulatory

Norgine gets first EU approval for WHIM syndrome therapy

pharminent April 30, 2026

Regulatory

AZ, Amgen will pilot FDA’s real-time clinical trial plan

pharminent April 29, 2026

Regulatory

AstraZeneca faces uphill battle at upcoming adcomm in face of FDA questions

pharminent April 29, 2026

You May Have Missed

Commercial

Lilly clocks 56% revenue increase in Q1 but declining prices stunt growth

pharminent April 30, 2026

M&A / Deals

Teva makes its first M&A play in years, buying Emalex

pharminent April 30, 2026

Pipeline

AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolio

pharminent April 30, 2026

Clinical Data

GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints

pharminent April 30, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.